Raxone® (idebenone 150 mg)

Santhera is the manufacturer of Raxone® (idebenone 150 mg), which is authorized in the European Union, Norway, Iceland and Liechtenstein for the treatment of Leber’s hereditary optic neuropathy (LHON) and is currently commercialized in 20 countries.


Leber’s hereditary optic neuropathy (LHON) is a heritable genetic disease causing blindness. The disease presents predominantly in young, otherwise healthy adult males as rapid, painless loss of central vision, usually leading to permanent bilateral blindness within a few months of the onset of symptoms. About 95% of patients harbour one of three pathogenic mutations of the mitochondrial DNA, which cause a defect in the complex I subunit of the mitochondrial respiratory chain. This defect leads to decreased cellular energy (ATP) production, increased reactive oxygen species (ROS) production and retinal ganglion cell dysfunction, which cause progressive loss of visual acuity and blindness.


Raxone circumvents the complex I defect and restores cellular energy levels in retinal ganglion cells and promotes recovery of visual acuity.


For more info and to get the SmPC of Raxone please visit http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003834/WC500193836.pdf